Applied Genetic Technologies Corporation

Last updated
Applied Genetic Technologies Corporation
Company type Public
Nasdaq:  AGTC
Russell Microcap Index component
Industry Biotechnology
FoundedJanuary 19, 1999;26 years ago (1999-01-19)
Headquarters Alachua, Florida, United States
Key people
Revenue
  • Decrease2.svg US$ 24.19 million
  • (FY JUN 30, 2018)
  • Decrease2.svg US$ -22.38 million
  • (FY JUN 30, 2018)
  • Decrease2.svg US$ -21.30 million
  • (FY JUN 30, 2018)
Total assets
  • Decrease2.svg US$ 118.53 million
  • (FY JUN 30, 2018)
Total equity
  • Decrease2.svg US$ 99.18 million
  • (FY JUN 30, 2018)
Number of employees
  • 78
  • (FY JUN 30, 2018)
Website AGTC.com
Footnotes /references
[1]

The Applied Genetic Technologies Corporation was a publicly traded [2] biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida. [3] In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer. [4]

The company focuses on ophthalmologic genetic diseases. The company's technologies are aimed at products that might have the potential to treat achromatopsia, X-linked retinoschisis, [5] [6] X-linked retinitis pigmentosa, [7] and age-related macular degeneration. [8] The company has six products in various stages of development; as of 2016, none had yet been approved. [9]

In January 2017, AGTC entered into a strategic research and development collaboration with Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding. Through the collaboration, AGTC and Bionic Sight will to develop a new optogenetic therapy that leverages AGTC's deep experience in gene therapy and ophthalmology. [10]

On January 9, 2020, the company reported positive results from a Phase 1/2 trial for its investigational gene therapy for retinitis pigmentosa. [11]  A few weeks later, the company reported interim six-month data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. [12] Applied Genetic Technologies Corporation is a patient partner within the blinding eye disease and rare disease community, including organizations like Foundation for Fighting Blindness and Global Genes. [13]

The company was acquired by Syncona, Dec 1 2022. [14]

References

  1. ↑ "US SEC: Form 10-K Applied Genetic Technologies Corporation". U.S. Securities and Exchange Commission. September 11, 2018. Retrieved December 1, 2018.
  2. ↑ "Applied Genetic Technologies Corporation (AGTC)". NASDAQ.com. Retrieved 4 January 2016.
  3. ↑ "Company Overview of Applied Genetic Technologies Corporation". Bloomberg . Retrieved November 15, 2016.
  4. ↑ "AGTC Announces New Leadership Appointments". Applied Genetic Technologies Corporation. Retrieved 2020-03-26.
  5. ↑ Chen, Angela. "Biogen to Pay Applied Genetic $124 Million to Develop Eye-Disease Treatments". Wall Street Journal. Retrieved 4 January 2016.
  6. ↑ "AGTC Announces Data Evaluating the Natural History of Patients With X-Linked Retinoschisis at the 48th Annual Retina Society Meeting". Yahoo Finance. Retrieved 4 January 2016.[ dead link ]
  7. ↑ "Biogen enters eye-treatment arena with AGTC deal". Reuters. 2 July 2015. Retrieved 4 January 2016.
  8. ↑ Ballie, Katherine. "Penn-Michigan State Team Develops Novel Gene Therapy for Achromatopsia". www.upenn.edu. Archived from the original on 27 October 2015. Retrieved 4 January 2016.
  9. ↑ "Finding Cures for Visual Disorders l Products". www.agtc.com. Archived from the original on 5 January 2016. Retrieved 4 January 2016.
  10. ↑ "Collaborations". agtc.com. Retrieved 2020-03-13.
  11. ↑ Lee, Jaimy. "Applied Genetic Technologies' stock rockets on early-stage eye therapy data". MarketWatch. Retrieved 2020-02-25.
  12. ↑ "AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia". Applied Genetic Technologies Corporation. Retrieved 2020-03-04.
  13. ↑ "Patient Partners". agtc.com. Retrieved 2020-04-02.
  14. ↑ https://www.globenewswire.com/news-release/2022/12/01/2565756/30580/en/Syncona-Limited-Portfolio-Company-Successfully-Completes-Tender-Offer-and-Acquisition-of-Applied-Genetic-Technologies-Corporation.html


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.